perphenazine has been researched along with Cognition Disorders in 4 studies
Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.
perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
Excerpt | Relevance | Reference |
---|---|---|
"363 hospital-based psychiatric patients in India, Romania, and United States aged 18 to 65 years and meeting criteria for DSM-IV-TR diagnosis of chronic schizophrenia were randomized double-blind to receive BL-1020 10 mg/d, BL-1020 20-30 mg/d, placebo, or risperidone (2-8 mg/d) for 6 weeks." | 5.16 | Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study. ( Anand, R; Davidson, M; Geffen, Y; Keefe, R; Rabinowitz, J, 2012) |
"Randomized, double-blind study of patients with schizophrenia assigned to receive treatment with olanzapine, perphenazine, quetiapine fumarate, or risperidone for up to 18 months as reported previously by Lieberman et al." | 5.12 | Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. ( Bilder, RM; Capuano, G; Davis, CE; Davis, SM; Gold, JM; Green, MF; Harvey, PD; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Meltzer, HY; Palmer, BW; Perkins, DO; Rosenheck, RA; Stroup, TS; Swartz, MS, 2007) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Crespo-Facorro, B | 1 |
Rodríguez-Sánchez, JM | 1 |
Pérez-Iglesias, R | 1 |
Mata, I | 1 |
Ayesa, R | 1 |
Ramirez-Bonilla, M | 1 |
Martínez-Garcia, O | 1 |
Vázquez-Barquero, JL | 1 |
Yolken, RH | 1 |
Torrey, EF | 1 |
Lieberman, JA | 2 |
Yang, S | 1 |
Dickerson, FB | 1 |
Geffen, Y | 1 |
Keefe, R | 1 |
Rabinowitz, J | 1 |
Anand, R | 1 |
Davidson, M | 1 |
Keefe, RS | 1 |
Bilder, RM | 1 |
Davis, SM | 1 |
Harvey, PD | 1 |
Palmer, BW | 1 |
Gold, JM | 1 |
Meltzer, HY | 1 |
Green, MF | 1 |
Capuano, G | 1 |
Stroup, TS | 1 |
McEvoy, JP | 1 |
Swartz, MS | 1 |
Rosenheck, RA | 1 |
Perkins, DO | 1 |
Davis, CE | 1 |
Hsiao, JK | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Double Blind Placebo Controlled Study of Valaciclovir in Treatment of Psychosis in Patients With Schizophrenia[NCT01364792] | Phase 2 | 24 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study to Determine the Efficacy, Tolerability and Safety of Low and High Non-overlapping Dose Ranges of BL-1020 Compared to Placebo and Risperidone[NCT00567710] | Phase 2 | 360 participants (Anticipated) | Interventional | 2008-07-31 | Completed | ||
Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis[NCT02634684] | Phase 2 | 82 participants (Actual) | Interventional | 2014-07-01 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The T-score indicates the performance on a neurocognitive battery of tests. Higher score reflects better performance. (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
Intervention | standardized T-score (Mean) | |
---|---|---|
placebo | amphetamine | |
Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 57.870 | 56.000 |
Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 54.476 | 55.476 |
Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 39.895 | 38.105 |
Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 31.895 | 33.842 |
"PPI was assessed with 42 trials of 6 types: 118 dB 40 ms pulse alone (P) & the same P preceded 10, 20, 30, 60, or 120 ms by a prepulse (pp) 16 dB over background. Startle magnitude (SM), habituation, latency & latency facilitation were measured to interpret changes in PPI.~%PPI = 100 x [(SM on P trials) - (SM on pp+P trials)] / SM on P trials. Example:~SM on P trials = 80 units SM on pp+P trials = 30 units %PPI = 100 x (80-30)/80 = 100 x 50/80 = 62.5%~Greater %PPI mean the reflex has been inhibited to a greater extent in the presence of a pp.~%PPI can't exceed 100: when SM on pp+P trials = 0, then %PPI = 100 x (SM on P trials - 0)/SM on P trials = 100 x 1 = 100%.~However, %PPI can theoretically be infinitely negative since SM on pp+P trials could be infinitely large (prepulse facilitiation (PPF)), i.e. SM is potentiated in the presence of a pp. PPF is normal at very short & very long pp intervals, but not within a species-specific physiological range of intervals." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
Intervention | % inhibition of startle (Mean) | |
---|---|---|
Placebo | Amphetamine | |
Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 50.626 | 53.029 |
Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 50.626 | 45.822 |
Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 41.162 | 39.545 |
Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 22.629 | 32.656 |
"Auditory discrimination learning: Subjects identify direction (up vs. down) of 2 consecutive sound sweeps. Parameters (e.g. inter-sweep interval, sweep duration) are established for subjects to maintain 80% correct responses. On screen and test days, subjects complete 1h of TCT. Analytic software yields the key measures: auditory processing speed (APS) and APS learning. APS is the shortest inter-stimulus interval at which a subject performs to criteria and APS learning is the difference (ms) between the first APS and the best APS of the subsequent trials. A smaller APS reflects better discrimination (i.e., subject correctly identified frequency sweep direction despite a smaller ms gap between stimuli) and a larger ms value for APS learning reflects more learning, i.e., faster APS with repeated trials. Limits for APS are capped at 0-to-1000 ms; values for APS learning are capped at (-) 1000-to-APS." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
Intervention | msec (Mean) | |
---|---|---|
placebo | amphetamine | |
Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | -2.113 | 29.190 |
Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 5.911 | 35.905 |
Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | -50.158 | 101.000 |
Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | -15.118 | 52.647 |
4 trials available for perphenazine and Cognition Disorders
Article | Year |
---|---|
Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Cognition Disorders; Fe | 2009 |
Serological evidence of exposure to Herpes Simplex Virus type 1 is associated with cognitive deficits in the CATIE schizophrenia sample.
Topics: Analysis of Variance; Antibodies, Viral; Antipsychotic Agents; Cognition Disorders; Double-Blind Met | 2011 |
Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cognition Disorders; Dopamine Antagonists; Double-Bli | 2012 |
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Cohort Studies; Dibenzothiazepine | 2007 |